SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

FDA approval of FAYUVI (UX111) as the first approved treatment for Sanfilippo syndrome type A, along with a Priority Review Voucher, is driving attention and expectations for a commercial launch. Traders are divided between viewing the approval, voucher value and broader pipeline as undervalued versus concerns about the small eligible population, one-time treatment, safety monitoring, cash burn and the stocks muted reaction.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

A Ninth Circuit ruling that states can regulate or ban sports-event contracts offered by prediction markets such as Kalshi was viewed as a regulatory win for DraftKings, potentially reducing a major competitive threat to licensed sportsbooks. Traders remain divided over whether the decision will materially improve DraftKings outlook, given ongoing appeals, its own investment in prediction markets, and concerns about competition, margins, and execution.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Anticipation of Helus Pharmas pivotal HLP003 Phase 3 APPROACH readout is driving attention after enrollment was completed ahead of schedule, with topline data expected in Q4 2026. Traders are encouraged by the new CEO, reported insider buying and strong prior clinical results, while others cite dilution risk and warn that profit-taking or disappointing data could reverse the rally.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckins expanded share-repurchase program is driving attention, with traders debating whether buybacks will reduce the float and support long-term value or instead facilitate insider selling and keep the OTC stock range-bound. Optimistic traders also connect the repurchase activity with a potential future relisting, while skeptics remain focused on persistent low volume and weak price action.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

The Federal Reserves 25-basis-point rate hike and signal of potentially further tightening have intensified debate around small-cap exposure, with traders noting IWMs sensitivity to higher borrowing costs, Treasury yields, and inflation. The community is divided between bearish views calling for continued downside and tactical traders expecting an oversold rebound or short squeeze amid elevated volatility.

Forgent Power Solutions, Inc. is a holding company, which engages in the design and manufacture of electrical distribution equipment used in data centers, power grid, and energy-intensive industrial facilities. It also offers powertrain solutions and standard and custom products. The company was founded on July 21, 2025 and is headquartered in Dayton, MN.

Forgent Power Solutions Inc. - Ordinary Shares - Class A

Forgent Power Solutions Inc.

A strong quarterly report, record bookings and backlog, and an above-consensus fiscal 2027 outlook have renewed enthusiasm for Forgents role in supplying power infrastructure for AI data centers. Traders are broadly bullish on the growth and analyst upgrades, though some remain concerned about dilution, the Neos ownership overhang, and whether the post-earnings rally can hold.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

A sharp rally has focused attention on NEARs AI and agent-infrastructure narrative, including chain abstraction, NEAR Intents, privacy features, and token buyback/fee-capture claims that traders view as potential utility catalysts. Sentiment is broadly bullish, though technical traders warn of resistance, profit-taking, and possible short-term pullbacks while others attribute the move to momentum and rotation from Zcash and other altcoins.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

A sharp post-earnings selloff has driven attention, with traders debating whether Dutch Bros premium valuation, slowing growth and discretionary-spending concerns justify the decline despite strong reported growth and continued store expansion. The failed or contested Salad and Go acquisition, insider selling and dilution concerns are also cited by bears, while bulls view the drop as an oversold buying opportunity.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Reported buying by CEO Ryan Cohen, along with anticipation of additional filings or share buybacks, is driving attention around GameStop. Traders are also debating whether rising buy pressure, elevated warrant borrowing costs, and call-option activity could fuel a short-squeeze or gamma move, while some remain skeptical given the stocks low volume and range-bound trading.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Reported FDA approval of Ultragenyxs FAYUVI gene therapy, formerly Abeonas UX111, is driving attention as traders expect milestone payments and royalties for ABEO. The community is broadly bullish on the added revenue stream, though some question the therapys limited rare-disease market and potential commercial scale.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$AGNC looking tasty to get back in here again